Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $30.74 USD
Change Today +1.05 / 3.54%
Volume 202.3K
EBS On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

emergent biosolutions inc (EBS) Snapshot

Open
$29.80
Previous Close
$29.69
Day High
$30.89
Day Low
$29.70
52 Week High
04/27/15 - $31.33
52 Week Low
10/15/14 - $19.31
Market Cap
1.2B
Average Volume 10 Days
225.3K
EPS TTM
$0.93
Shares Outstanding
38.3M
EX-Date
--
P/E TM
33.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for EMERGENT BIOSOLUTIONS INC (EBS)

emergent biosolutions inc (EBS) Related Businessweek News

No Related Businessweek News Found

emergent biosolutions inc (EBS) Details

Emergent BioSolutions Inc. develops, manufactures, and commercializes immunobiotics such as vaccines and immune globulins that assist the body’s immune system. The company’s biodefense segment develops, manufactures, and commercializes drugs such as BioThrax, a vaccine for the prevention of anthrax, for use against biological agents. Other products in preclinical development include drugs for the treatment of patients after they are exposed to anthrax and botulinum toxin. Emergent’s commercial segment develops products for use against infectious diseases. These include a single-dose typhoid vaccine in phase II clinical development; a hepatitis B vaccine in phase II clinical development, and a group B streptococcus vaccine for women of childbearing age for protection of the fetus and newborn babies, which is in phase I clinical trials. Emergent is also developing chlamydia and meningitis B vaccines. Emergent primarily works for the U.S. Defense and Health & Human Services departments. It has collaboration agreements with the British Health Protection Agency for the development of a human botulinum immune globulin candidate and with Sanofi Pasteur for the development of meningitis B vaccine candidate. The company, which was founded in 1998, is based in Rockville, Maryland.

1,280 Employees
Last Reported Date: 03/9/15
Founded in 1998

emergent biosolutions inc (EBS) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $1.2M
Founder, Executive Chairman, Chairman of Stra...
Total Annual Compensation: $881.5K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $659.5K
Executive Vice President and President of Bio...
Total Annual Compensation: $623.1K
Executive Vice President and President of Bio...
Total Annual Compensation: $558.7K
Compensation as of Fiscal Year 2014.

emergent biosolutions inc (EBS) Key Developments

Emergent BioSolutions, Inc. Expands Commercial Product Portfolio With FDA Approval of IXINITY, a Recombinant Factor IX Treatment for Hemophilia B

Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration (FDA) has approved IXINITY® [coagulation factor IX (recombinant)], an intravenous recombinant human coagulation factor IX therapeutic for the control and prevention of bleeding episodes and for perioperative management in adults and children, =12 years of age, with Hemophilia B. Hemophilia B is a bleeding disorder caused by a mutation on the factor IX gene resulting in a deficiency of clotting factor IX in the blood, which controls bleeding. The approval of IXINITY is based on a global clinical trial in which IXINITY showed a mean incremental recovery of 0.98 IU/dL and a mean terminal half-life of 24 hours. IXINITY is a third-generation1 treatment with no factor IX inhibitors developed in clinical trials. Simultaneous with this approval, the company is launching the IXINITY IXperience™ Concierge, available at 1-855-IXINITY, which will provide information on IXINITY and other programs designed with the needs of people with Hemophilia B and their community in mind.

Emergent BioSolutions, Inc. Re-Affirms Earnings Guidance for the First Quarter and Full Year of 2015

Emergent BioSolutions Inc. announced that it has resumed full manufacturing operations of BioThrax (Anthrax Vaccine Adsorbed) after completing its internal manufacturing investigation of foreign particles discovered in a limited number of vials in two manufactured BioThrax lots. With the conclusion of its investigation, the company reaffirmed earnings guidance for the first quarter and full year of 2015. For the full year of 2015, the company re-affirmed its previous forecast of total revenues of $510 to $540 million, driven by growth in BioThrax sales which are anticipated to be between $270 to $285 million, continued domestic and international sales of the other Biodefense division products, incremental growth in product sales and services revenues from the Biosciences division and continued robust development funding through contracts, grants and collaborations revenues. The company also forecasts GAAP net income of $50 to $60 million and adjusted net income of $60 to $70 million. For the first quarter of 2015, the company expects total revenues of $62-$64 million and a net loss of $21-$23 million.

Emergent Biosolutions Signs Contract with Barda for Anthrax Vaccine

Emergent BioSolutions Inc. has signed a contract with the Biomedical Advanced Research and Development Authority, or BARDA, for the advanced development of NuThrax, or anthrax vaccine adsorbed with CPG 7909 adjuvant. The contract, valued at $31 million, consists of a 30 month base period of performance to develop NuThrax for post-exposure prophylaxis of anthrax disease. Activities to be completed under the contract include process validation, consistency lot manufacture, assay validation, non-clinical studies, and start-up activities in preparation for the Phase III clinical trial. Emergent looks forward to working with BARDA to advance the development of NuThrax towards a Phase III study.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EBS:US $30.74 USD +1.05

EBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $17.98 USD -0.08
Chimerix Inc $35.34 USD +1.34
Depomed Inc $23.86 USD +0.60
Nektar Therapeutics $11.48 USD +1.96
Skyepharma PLC 278.00 GBp -22.00
View Industry Companies
 

Industry Analysis

EBS

Industry Average

Valuation EBS Industry Range
Price/Earnings 38.3x
Price/Sales 2.6x
Price/Book 2.1x
Price/Cash Flow 32.1x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMERGENT BIOSOLUTIONS INC, please visit www.emergentbiosolutions.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.